A Phase 4 interventional study of 2% povidone-iodine and 2% povidone-iodine in Viral Conjunctivitis, sponsored by Mahidol University. Completed at 1 site in Thailand. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2010-08-11.
Sponsored by Mahidol University · Phase 4, Interventional, and Treatment
The purpose of this study is to determine the outcomes of treating epidemic keratoconjunctivitis with 2% povidone-iodine.
The study design was a prospective interventional case series. Our institutional ethical committee approved the study protocol in April 2004. We performed this study between July 2004 and December 2009. During this period, there were 2 episodes of EKC epidemic. The first episode was in 2006 and the second in 2009.
361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.
This study's enrollment of 172 is above the median of 100 across 299 interventional studies indexed under Conjunctivitis.
Browse Conjunctivitis studies →Mahidol University is the lead sponsor of 731 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: 2% povidone-iodine
apply 4 times a day for one week
Also known as: PVP-I
apply 2% povidone-iodine 4 times per day for one week
Also known as: PVP-I
the recovery rate within one week of treatment
Time frame: 1 week
drug tolerability
proportion of patient who can continue topical application of povidone-iodine for a week or until EKC subsides
Time frame: 1 week
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Conjunctivitis, Viral
Mahidol University